US: 1.917.963.8646 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Schizophrenia Drugs market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Schizophrenia Drugs market." Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to understand reality. Common symptoms include false beliefs, unclear or confused thinking, hearing voices that others do not, reduced social engagement and emotional expression, and a lack of motivation. The global Schizophrenia Drugs market is valued at 5310 million US$ in 2018 is expected to reach 6470 million US$ by the end of 2025, growing at a CAGR of 2.5% during 2019-2025. This report focuses on Schizophrenia Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Schizophrenia Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: Johnson & Johnson Bristol-Myers Squibb Otsuka Pharma AstraZeneca Sumitomo Dainippon Eli Lilly Alkermes Vanda Pharma Allergan Pfizer Segment by Regions North America Europe China Japan Segment by Type Oral Antipsychotics Injectable Antipsychotics Segment by Application Hospital Clinic
Table of Contents Executive Summary 1 Schizophrenia Drugs Market Overview 1.1 Product Overview and Scope of Schizophrenia Drugs 1.2 Schizophrenia Drugs Segment by Type 1.2.1 Global Schizophrenia Drugs Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Oral Antipsychotics 1.2.3 Injectable Antipsychotics 1.3 Schizophrenia Drugs Segment by Application 1.3.1 Schizophrenia Drugs Consumption Comparison by Application (2014-2025) 1.3.2 Hospital 1.3.3 Clinic 1.4 Global Schizophrenia Drugs Market by Region 1.4.1 Global Schizophrenia Drugs Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global Schizophrenia Drugs Market Size 1.5.1 Global Schizophrenia Drugs Revenue (2014-2025) 1.5.2 Global Schizophrenia Drugs Production (2014-2025) 2 Global Schizophrenia Drugs Market Competition by Manufacturers 2.1 Global Schizophrenia Drugs Production Market Share by Manufacturers (2014-2019) 2.2 Global Schizophrenia Drugs Revenue Share by Manufacturers (2014-2019) 2.3 Global Schizophrenia Drugs Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Schizophrenia Drugs Production Sites, Area Served, Product Types 2.5 Schizophrenia Drugs Market Competitive Situation and Trends 2.5.1 Schizophrenia Drugs Market Concentration Rate 2.5.2 Schizophrenia Drugs Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Schizophrenia Drugs Production Market Share by Regions 3.1 Global Schizophrenia Drugs Production Market Share by Regions 3.2 Global Schizophrenia Drugs Revenue Market Share by Regions (2014-2019) 3.3 Global Schizophrenia Drugs Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America Schizophrenia Drugs Production 3.4.1 North America Schizophrenia Drugs Production Growth Rate (2014-2019) 3.4.2 North America Schizophrenia Drugs Production, Revenue, Price and Gross Margin (2014-2019) 3.5 Europe Schizophrenia Drugs Production 3.5.1 Europe Schizophrenia Drugs Production Growth Rate (2014-2019) ... | read more...